Evozyne, a pharmaceutical development generative AI company invested by Nvidia

Evozyne, LLC, founded in 2020 and headquartered in Chicago, Illinois, USA, is a company focusing on the generation of therapeutic discovery and drug development artificial intelligence Company.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne Encyclopedia of US Stocks

Evozyne specializes in protein design and molecular scale Biotechnology Company 。 Its mission is to unleash the potential of new proteins through radical changes in protein design to address complex human and social challenges. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne is committed to manufacturing new proteins to address the long-term challenges of therapeutic development. By improving the performance of proteins to an unprecedented level, Evozyne has provided solutions on a commercial scale, paving the way for new products and contributing to a healthier world. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne technology: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne uses evolutionary deep learning to simulate millions of years of evolution in the laboratory. Proteins make living things work. Evozyne's mission is to create new proteins that solve key problems. In order to achieve this goal, the company turned to the theory of evolution for guidance and found a set of revolutionary principles to explain the function of proteins. Evozyne uses this knowledge to produce adaptive, high-performance proteins to address long-term therapeutic challenges. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne Products: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne's products are high-performance, adaptive proteins with extremely advanced functions. The company is looking for treatment methods that can change the life of patients and may cure incurable diseases. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne Financing Encyclopedia

In April 2020, Evozyne received $9.2 million in venture capital. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

In April 2021, Evozyne completed round A financing of US $54.2 million. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

In September 2023, Evozyne will complete Fidelity and OrbiMed Round B financing of $81 million led by investors, Valor Equity Partners , NVentures and Paragon Biosciences. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/evozyne.html

Evozyne US equity investment

Unlisted company , official website of the company, waiting for Evozyne IPO Listing.